Resultados: 19

Cost-minimization analysis of biological disease-modifying antirheumatic drugs in the Brazilian public health system (SUS) considering patients’ weight

Yazawa, Priscila Yuri; Puopolo, Giovanna Renelo; Walmrath, Juliana; Leme-Souza, Rafael; Bianco, Juares.

J. bras. econ. saúde (Impr.); 11 (2), 2019

Objective: To perform a cost-minimization analysis comparing the cohort with the current average patient weight of 70 kg (MoH current assumption). Since most rheumatoid arthritis (RA) patients in Brazil are women (60 kg or less), we also aimed to define this percentage at Brazilian public healthcare syst...

Artrite Reumatoide, Custos e Análise de Custo, Sistema Único de Saúde

Texto completo (link principal)     Texto completo (link alternativo)    

The influence of reproductive information quality on the probability of unplanned and unwanted pregnancies in Brazil

Wichmann, Roberta Moreira.

J. bras. econ. saúde (Impr.); 11 (1), 2019

Background: Unplanned pregnancies are a significant risk factor for inadequate use of prenatal care, and unplanned newborns are prone to having low birth weight. Women with unplanned pregnancies have a higher probability of reporting medical problems before and during pregnancy. In fact, the wellbeing of...

Complicações na Gravidez, Reprodução, Fatores Socioeconômicos

Texto completo (link principal)     Texto completo (link alternativo)    

Treatment patterns of Hodgkin’s lymphoma in Brazil: experts’ perspective

Silveira, Talita Bueno da; Buccheri, Valeria; Perini, Guilherme Fleury; Bigni, Ricardo De Saga; Penna, Adriana Marques Damasco; Pimenta, Flavia Cristina Fernades; Cerci, Juliano Julio; Bacchi, Carlos Eduardo; Oliveira, Renato Watanabe de; Barreto, Tania.

J. bras. econ. saúde (Impr.); 10 (2), 2018

Background: Hodgkin’s Lymphoma (HL) is a curable type of cancer, with a wide variety of therapies, especially for refractory/relapsing cases. Therefore, the study aims to explore the treatment patterns used in the management of HL patients in Brazil. Methods: A survey was developed to explore the treat...

Doença de Hodgkin, Tratamento Farmacológico, Pesquisas sobre Atenção à Saúde

Texto completo (link principal)     Texto completo (link alternativo)    

Unmet needs in multiple myeloma in Brazil from physicians’ perspective – barriers in quality of life and disease management

Maiolino, Angelo; Pinto Neto, Jorge Vaz; Leite, Leonardo Gomes Teixeira; Seguro, Fernanda Salles; Braga, Walter Moisés Tobias; Zanella, Karla Richter; Nascimento Sobrinho, Jairo Jose do; Oliveira, Renato Watanabe de; Julian, Guilherme Silva; Tanaka, Paula Yurie.

J. bras. econ. saúde (Impr.); 10 (2), 2018

Objective: There is an increasing trend of the overall survival rates of multiple myeloma (MM) patients over the years, increasing the necessity to improve their quality of life and attenuate unmet medical needs. Therefore, this study aims to explore and describe unmet medical needs and barriers in Brazi...

Mieloma Múltiplo, Qualidade de Vida, Atenção à Saúde

Texto completo (link principal)     Texto completo (link alternativo)    

Hodgkin’s lymphoma unmet medical needs in Brazil: experts’ perspective

Buccheri, Valeria; Perini, Guilherme Fleury; Penna, Adriana Marques Damasco; Silveira, Talita Bueno da; Bigni, Ricardo De Sa; Pimenta, Flavia Cristina Fernandes; Cerci, Juliano Julio; Bacchi, Carlos Eduardo; Oliveira, Renato Watanabe de; Barreto, Tania.

J. bras. econ. saúde (Impr.); 10 (2), 2018

Background: In 2016, Hodgkin’s Lymphoma (HL) was responsible for 2,470 new cases in Brazil and, despite recent scientific advances, there are unmet medical needs that affects patients’ outcome. Therefore, we aimed to explore the unmet medical needs in the management of HL patients in Brazil, based on...

Doença de Hodgkin, Necessidades e Demandas de Serviços de Saúde, Assistência ao Paciente

Texto completo (link principal)     Texto completo (link alternativo)    

Cost-effectiveness and budgetary impact of lipegfilgrastim for the reduction of chemotherapy-induced neutropenia in Brazil

Szende, Agota; Urwongse, Jennifer; Szabo, Erika; Klastersky, Jean; Mueller, Udo W; Stefani, Stephen D; Tang, Boxiong.

J. bras. econ. saúde (Impr.); 10 (2), 2018

Background: Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of chemotherapy-induced neutropenia. Lipegfilgrastim is a long-acting, once-per-cycle G-CSF, while Brazil’s standard of care is short-acting filgrastim. A cost-effectiveness and budget impact analysis of lipegfilgrastim was con...

Fator Estimulador de Colônias de Granulócitos, Custos e Análise de Custo, Neutropenia

Texto completo (link principal)     Texto completo (link alternativo)    

Cost variation of antipsychotics in the public health system in Brazil: the implication for health resource use

Razzouk, Denise.

J. bras. econ. saúde (Impr.); 9 (Suplemento 1), 2017

Objective: This study aimed to verify the variation on antipsychotics costs according to four unit costs paid by public health providers in Brazil. Methods: This cross-sectional study used the health provider perspective and bottom-up approach to evaluate 134 subjects with mental disorders, in regular us...

Antipsicóticos, Custos e Análise de Custo, Serviços Comunitários de Saúde Mental, Política de Saúde, Transtornos Mentais, Alocação de Recursos

Texto completo (link principal)     Texto completo (link alternativo)    

The economic impact of providing dengue vaccination in the workplace in Brazil

Durand, Laure; Grailles, Louise; Boissière, Christophe; Beucher, Sophie.

J. bras. econ. saúde (Impr.); 9 (Suplemento 1), 2017

Objective: To estimate the economic value of implementing a workplace dengue vaccination program from an employer perspective. Methods: The cost of a vaccination program was compared with the economic benefits in terms of reduced absenteeism and presenteeism in companies in Brazil. Input data were obtain...

Vacinação, Dengue, 16359, Análise Custo-Benefício

Texto completo (link principal)     Texto completo (link alternativo)    

Análise de custo-efetividade da toxina onabotulínica A no tratamento preventivo da migrânea crônica sob a perspectiva do sistema privado de saúde do Brasil

Piovesan, Elcio; Cadecaro, Patricia; Pepe, Camila.

J. bras. econ. saúde (Impr.); 9 (Suplemento 1), 2017

Objetivo: Avaliar o custo-efetividade da toxina onabotulínica A (TB) versus ausência de tratamento “não tratar” (NT) da migrânea crônica refratária a pelo menos dois medicamentos em um Sistema de Saúde Suplementar. Métodos: Modelo analítico de decisão simulou desfechos e custos em 24 semana...

Análise Custo-Benefício, Cefaleia, Toxinas Botulínicas Tipo A, Saúde Suplementar

Texto completo (link principal)     Texto completo (link alternativo)    

Custo-efetividade de terapias anti-PD-1 comparadas com ipilimumabe para o tratamento de melanoma avançado sob a perspectiva do sistema de saúde suplementar brasileiro

Tanaka, Straus; Aratangy, Guilherme; Carelli, Guareide; Fahham, Lucas; Pepe, Camila; Bernardino, Graziela.

J. bras. econ. saúde (Impr.); 9 (Suplemento 1), 2017

Objetivo: Realizar uma análise de custo-efetividade das terapias imuno-oncológicas anti-PD-1 aprovadas no Brasil versus ipilimumabe no tratamento do paciente sem tratamento prévio com melanoma metastático (estádios III ou IV), independentemente da mutação BRAF sob a perspectiva do sistema de saúd...

Análise Custo-Benefício, Melanoma, Saúde Suplementar

Texto completo (link principal)     Texto completo (link alternativo)